Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective

Crohn’s disease (CD) is associated with reduced quality of life, increased absenteeism and high direct medical costs resulting from frequent hospitalizations and surgeries. Tumor necrosis factor–alpha inhibitors (TNFi’s) have transformed the therapeutic landscape and enabled a shift from a symptom c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakatos, Peter L, Kaplan, Gilaad G, Bressler, Brian, Khanna, Reena, Targownik, Laura, Jones, Jennifer, Rahal, Yasmine, McHugh, Kevin, Panaccione, Remo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340647/
https://www.ncbi.nlm.nih.gov/pubmed/35919766
http://dx.doi.org/10.1093/jcag/gwac001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340647/
https://www.ncbi.nlm.nih.gov/pubmed/35919766
http://dx.doi.org/10.1093/jcag/gwac001

Ejemplares similares